DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Drug repurposing for antimicrobial discovery

Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy

Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors